Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition

Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal year 2026. | BMS and Hengrui signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal 2026. Daiichi Sankyo aims to be a global top-5 oncology player while expanding beyond antibody-drug conjugates. Plus more.